{
    "medicine_id": "7fbbc6c35a0afc8824d47f8ab545b667b48d859e",
    "platform_id": "DB00630",
    "metadata": {
        "name": "Accel alendronate 35 mg Tablet",
        "composition": "35 mg Alendronic acid",
        "clinical_particulars": {
            "therapeutic_indications": "Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women treatment of glucocorticoid induced osteoporosis and Paget s disease of bone FDA Label A959 A176750 However alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance 35mL min FDA Label",
            "contraindications": {
                "disease": "In clinical studies 3 of patients experience abdominal pain acid regurgitation constipation diarrhea dyspepsia musculoskeletal pain and nausea FDA Label No information for treatment of overdose is available however patients should be given milk or antacids to bind alendronic acid and vomiting should not be induced FDA Label Patients may experience hypocalcemia hypophosphatemia and upper gastrointestinal events FDA Label There are currently no studies for safety and efficacy in pregnancy though studies in pregnant rats show fetal and maternal complications at 4 times the clinical dose and pregnant rabbits do not show complications at as high as 10 times the clincal dose FDA Label Excretion in breast milk and therefore safety in lactation is unknown FDA Label Alendronic acid has been studied for use in pediatric patients FDA Label The oral bioavailability is similar to that in adult patients but an increase in the portion of patients experiencing vomiting FDA Label There is no significant difference in efficacy or safety of alendronic acid in geriatric populations though there is potential for even greater sensitivity in patients at a further advanced age than those in the study FDA Label Alendronic acid is not recommended for patients with creatinine clearance 35mL min but no dosage adjustment is necessary in hepatic impairment FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Alendronic acid tablets have a very low oral bioavialability FDA Label A176750 After administration it distributes into soft tissue and bone or is excreted in the urine FDA Label Alendronic acid does not undergo metabolism FDA Label",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB01609",
                        "description": "The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Alendronic acid is combined with Deferasirox"
                    },
                    {
                        "drugbank-id": "DB00159",
                        "description": "The risk or severity of adverse effects can be increased when Icosapent is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00244",
                        "description": "The risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00328",
                        "description": "The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00461",
                        "description": "The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00465",
                        "description": "The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00469",
                        "description": "The risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00482",
                        "description": "The risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00500",
                        "description": "The risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00533",
                        "description": "The risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00554",
                        "description": "The risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00573",
                        "description": "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00580",
                        "description": "The risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00586",
                        "description": "The risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00605",
                        "description": "The risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00712",
                        "description": "The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00749",
                        "description": "The risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00784",
                        "description": "The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00788",
                        "description": "The risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00795",
                        "description": "The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00812",
                        "description": "The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00814",
                        "description": "The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00821",
                        "description": "The risk or severity of adverse effects can be increased when Carprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00861",
                        "description": "The risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00936",
                        "description": "The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00939",
                        "description": "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00945",
                        "description": "The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00991",
                        "description": "The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01009",
                        "description": "The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01014",
                        "description": "The risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01050",
                        "description": "The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01250",
                        "description": "The risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01283",
                        "description": "The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01397",
                        "description": "The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01399",
                        "description": "The risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01401",
                        "description": "The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01419",
                        "description": "The risk or severity of adverse effects can be increased when Antrafenine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01424",
                        "description": "The risk or severity of adverse effects can be increased when Aminophenazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01435",
                        "description": "The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01600",
                        "description": "The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01628",
                        "description": "The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB02224",
                        "description": "The risk or severity of adverse effects can be increased when Taxifolin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB03585",
                        "description": "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04725",
                        "description": "The risk or severity of adverse effects can be increased when Licofelone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04743",
                        "description": "The risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04812",
                        "description": "The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04817",
                        "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04828",
                        "description": "The risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB05095",
                        "description": "The risk or severity of adverse effects can be increased when Cimicoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06725",
                        "description": "The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06736",
                        "description": "The risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06737",
                        "description": "The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB07402",
                        "description": "The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08439",
                        "description": "The risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08797",
                        "description": "The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08940",
                        "description": "The risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08942",
                        "description": "The risk or severity of adverse effects can be increased when Isoxicam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08951",
                        "description": "The risk or severity of adverse effects can be increased when Indoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08955",
                        "description": "The risk or severity of adverse effects can be increased when Ibuproxam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08976",
                        "description": "The risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08981",
                        "description": "The risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08984",
                        "description": "The risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08991",
                        "description": "The risk or severity of adverse effects can be increased when Epirizole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09084",
                        "description": "The risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09213",
                        "description": "The risk or severity of adverse effects can be increased when Dexibuprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09214",
                        "description": "The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09215",
                        "description": "The risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09216",
                        "description": "The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09217",
                        "description": "The risk or severity of adverse effects can be increased when Firocoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09218",
                        "description": "The risk or severity of adverse effects can be increased when Clonixin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09285",
                        "description": "The risk or severity of adverse effects can be increased when Morniflumate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09288",
                        "description": "The risk or severity of adverse effects can be increased when Propacetamol is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09295",
                        "description": "The risk or severity of adverse effects can be increased when Talniflumate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11455",
                        "description": "The risk or severity of adverse effects can be increased when Robenacoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11466",
                        "description": "The risk or severity of adverse effects can be increased when Tepoxalin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11518",
                        "description": "The risk or severity of adverse effects can be increased when Flunixin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12399",
                        "description": "The risk or severity of adverse effects can be increased when Polmacoxib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12445",
                        "description": "The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12545",
                        "description": "The risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12610",
                        "description": "The risk or severity of adverse effects can be increased when Ebselen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13001",
                        "description": "The risk or severity of adverse effects can be increased when Tinoridine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13167",
                        "description": "The risk or severity of adverse effects can be increased when Alclofenac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13217",
                        "description": "The risk or severity of adverse effects can be increased when Fentiazac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13232",
                        "description": "The risk or severity of adverse effects can be increased when Suxibuzone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13286",
                        "description": "The risk or severity of adverse effects can be increased when Bumadizone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13314",
                        "description": "The risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13371",
                        "description": "The risk or severity of adverse effects can be increased when Difenpiramide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13407",
                        "description": "The risk or severity of adverse effects can be increased when Nifenazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13432",
                        "description": "The risk or severity of adverse effects can be increased when Lonazolac is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13481",
                        "description": "The risk or severity of adverse effects can be increased when Tenidap is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13524",
                        "description": "The risk or severity of adverse effects can be increased when Propyphenazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13527",
                        "description": "The risk or severity of adverse effects can be increased when Proglumetacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13538",
                        "description": "The risk or severity of adverse effects can be increased when Guacetisal is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13544",
                        "description": "The risk or severity of adverse effects can be increased when Ethenzamide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13612",
                        "description": "The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13629",
                        "description": "The risk or severity of adverse effects can be increased when Mofebutazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13649",
                        "description": "The risk or severity of adverse effects can be increased when Proquazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13657",
                        "description": "The risk or severity of adverse effects can be increased when Benorilate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13722",
                        "description": "The risk or severity of adverse effects can be increased when Pirprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13783",
                        "description": "The risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13860",
                        "description": "The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14059",
                        "description": "The risk or severity of adverse effects can be increased when SC 236 is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14060",
                        "description": "The risk or severity of adverse effects can be increased when NS 398 is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14938",
                        "description": "The risk or severity of adverse effects can be increased when Flurbiprofen axetil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09212",
                        "description": "The risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Bevacizumab is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00480",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Lenalidomide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01041",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Thalidomide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Sunitinib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01270",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Ranibizumab is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB02640",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Fumagillin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB02709",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Resveratrol is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04866",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB05288",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06423",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Endostatin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06436",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06461",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Squalamine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Pazopanib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06647",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Volociximab is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08633",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when TNP 470 is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08910",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Pomalidomide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11366",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Roquinimex is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11727",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Endostar is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12056",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Trebananib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12081",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12671",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Beloranib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14864",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Brolucizumab is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00213",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole"
                    },
                    {
                        "drugbank-id": "DB00338",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole"
                    },
                    {
                        "drugbank-id": "DB00448",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole"
                    },
                    {
                        "drugbank-id": "DB00736",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole"
                    },
                    {
                        "drugbank-id": "DB01129",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole"
                    },
                    {
                        "drugbank-id": "DB05351",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole"
                    },
                    {
                        "drugbank-id": "DB13762",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexrabeprazole"
                    },
                    {
                        "drugbank-id": "DB11964",
                        "description": "The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Ilaprazole"
                    },
                    {
                        "drugbank-id": "DB00017",
                        "description": "The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06773",
                        "description": "The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13189",
                        "description": "The risk or severity of hypocalcemia can be increased when Calcitonin porcine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13742",
                        "description": "The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00314",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00452",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00479",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00684",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00798",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00955",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00994",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01082",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01172",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01421",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB03615",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04263",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Geneticin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04626",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04729",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin C1a is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04808",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06696",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08437",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11512",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11520",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12604",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12615",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13540",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Isepamicin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00803",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01370",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium"
                    },
                    {
                        "drugbank-id": "DB01377",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide"
                    },
                    {
                        "drugbank-id": "DB01390",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate"
                    },
                    {
                        "drugbank-id": "DB06723",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide"
                    },
                    {
                        "drugbank-id": "DB06724",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium carbonate"
                    },
                    {
                        "drugbank-id": "DB08938",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate"
                    },
                    {
                        "drugbank-id": "DB09104",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide"
                    },
                    {
                        "drugbank-id": "DB09281",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium trisilicate"
                    },
                    {
                        "drugbank-id": "DB09481",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate"
                    },
                    {
                        "drugbank-id": "DB13209",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate"
                    },
                    {
                        "drugbank-id": "DB13249",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate"
                    },
                    {
                        "drugbank-id": "DB13280",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium acetoacetate"
                    },
                    {
                        "drugbank-id": "DB13322",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite"
                    },
                    {
                        "drugbank-id": "DB13486",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium peroxide"
                    },
                    {
                        "drugbank-id": "DB13595",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Almasilate"
                    },
                    {
                        "drugbank-id": "DB13626",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium glycinate"
                    },
                    {
                        "drugbank-id": "DB13650",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Aloglutamol"
                    },
                    {
                        "drugbank-id": "DB13829",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium silicate"
                    },
                    {
                        "drugbank-id": "DB14517",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate"
                    },
                    {
                        "drugbank-id": "DB00325",
                        "description": "Nitroprusside can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB06783",
                        "description": "Prussian blue can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09146",
                        "description": "Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09501",
                        "description": "Ferric ammonium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09507",
                        "description": "Ferumoxsil can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09508",
                        "description": "Ferumoxides can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11171",
                        "description": "Ferric sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11210",
                        "description": "Ferrous bisglycinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11417",
                        "description": "Gleptoferron can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11576",
                        "description": "Ferric oxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB12821",
                        "description": "Perflubutane can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13257",
                        "description": "Ferrous sulfate anhydrous can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13381",
                        "description": "Sodium feredetate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13423",
                        "description": "Ferric hydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13569",
                        "description": "Ferrous chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13949",
                        "description": "Ferric cation can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14488",
                        "description": "Ferrous gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14489",
                        "description": "Ferrous succinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14491",
                        "description": "Ferrous fumarate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14520",
                        "description": "Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14695",
                        "description": "Ferric oxyhydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB15598",
                        "description": "Ferric maltol can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB12208",
                        "description": "Iron isomaltoside 1000 can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB00653",
                        "description": "Magnesium sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09407",
                        "description": "Magnesium chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11110",
                        "description": "Magnesium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13359",
                        "description": "Magnesium aspartate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13749",
                        "description": "Magnesium gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13786",
                        "description": "Magnesium orotate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14514",
                        "description": "Magnesium levulinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14515",
                        "description": "Magnesium lactate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB00258",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium acetate"
                    },
                    {
                        "drugbank-id": "DB00326",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glucoheptonate"
                    },
                    {
                        "drugbank-id": "DB01164",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium chloride"
                    },
                    {
                        "drugbank-id": "DB01373",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium"
                    },
                    {
                        "drugbank-id": "DB11093",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium citrate"
                    },
                    {
                        "drugbank-id": "DB11126",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate"
                    },
                    {
                        "drugbank-id": "DB11348",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium Phosphate"
                    },
                    {
                        "drugbank-id": "DB13142",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate anhydrous"
                    },
                    {
                        "drugbank-id": "DB13231",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate"
                    },
                    {
                        "drugbank-id": "DB13365",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate gluconate"
                    },
                    {
                        "drugbank-id": "DB13590",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium pangamate"
                    },
                    {
                        "drugbank-id": "DB13800",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium levulinate"
                    },
                    {
                        "drugbank-id": "DB14577",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium cation"
                    },
                    {
                        "drugbank-id": "DB14684",
                        "description": "The serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil"
                    },
                    {
                        "drugbank-id": "DB09139",
                        "description": "The risk or severity of hypocalcemia can be increased when Alendronic acid is combined with Technetium Tc 99m oxidronate"
                    },
                    {
                        "drugbank-id": "DB00214",
                        "description": "The risk or severity of hypocalcemia can be increased when Torasemide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00695",
                        "description": "The risk or severity of hypocalcemia can be increased when Furosemide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00887",
                        "description": "The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00903",
                        "description": "The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB02925",
                        "description": "The risk or severity of hypocalcemia can be increased when Piretanide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB08961",
                        "description": "The risk or severity of hypocalcemia can be increased when Azosemide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00091",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00229",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00267",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmenoxime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00274",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00282",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00300",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00369",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00384",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00430",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpiramide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00438",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00447",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00456",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00493",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00512",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00515",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00529",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00563",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00567",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00577",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00626",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00681",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00689",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloglycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00718",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00738",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pentamidine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00742",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00787",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00833",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00923",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00958",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00999",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01066",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01072",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01111",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistimethate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01112",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01139",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01140",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01150",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01212",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01326",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01327",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01328",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01329",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01330",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01331",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01332",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01333",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01356",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium cation is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01413",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01414",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefacetrile is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01415",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01416",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lopinavir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB02247",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrolyzed Cephalothin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB03450",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalothin Group is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04570",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB04918",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftobiprole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB06590",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09008",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09062",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefminox is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB09299",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11367",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefroxadine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB11935",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Flomoxef is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB12151",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Brincidofovir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13266",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13461",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefcapene is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13470",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13499",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13504",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13638",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefbuperazone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13667",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefozopran is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13682",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13778",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazedone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13821",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftezole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB13868",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14126",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14713",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB01438",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14507",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium citrate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14509",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium carbonate is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB15066",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00399",
                        "description": "The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00720",
                        "description": "The risk or severity of adverse effects can be increased when Alendronic acid is combined with Clodronic acid"
                    },
                    {
                        "drugbank-id": "DB01077",
                        "description": "The risk or severity of adverse effects can be increased when Alendronic acid is combined with Etidronic acid"
                    },
                    {
                        "drugbank-id": "DB01133",
                        "description": "The risk or severity of adverse effects can be increased when Alendronic acid is combined with Tiludronic acid"
                    },
                    {
                        "drugbank-id": "DB06255",
                        "description": "The risk or severity of adverse effects can be increased when Alendronic acid is combined with Incadronic acid"
                    },
                    {
                        "drugbank-id": "DB00007",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00052",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Somatotropin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Infliximab is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00080",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00175",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Pravastatin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00181",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Baclofen is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00203",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Sildenafil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00224",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Indinavir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00227",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Lovastatin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00242",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Cladribine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00252",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Phenytoin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00358",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Mefloquine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00382",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Tacrine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00389",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Carbimazole is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00439",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Cerivastatin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00440",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Trimethoprim is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00443",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Betamethasone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00471",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Montelukast is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00495",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Zidovudine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00501",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Cimetidine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ritonavir is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00528",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Lercanidipine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00537",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ciprofloxacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Vincristine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00550",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Propylthiouracil is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00584",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Enalapril is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00585",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Nizatidine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00602",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ivermectin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00608",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Chloroquine is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00620",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Triamcinolone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00627",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Niacin is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00636",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Clofibrate"
                    },
                    {
                        "drugbank-id": "DB00641",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Simvastatin"
                    },
                    {
                        "drugbank-id": "DB00649",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Stavudine"
                    },
                    {
                        "drugbank-id": "DB00666",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Nafarelin"
                    },
                    {
                        "drugbank-id": "DB00688",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Mycophenolate mofetil"
                    },
                    {
                        "drugbank-id": "DB00704",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Naltrexone"
                    },
                    {
                        "drugbank-id": "DB00709",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Lamivudine"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00818",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Propofol"
                    },
                    {
                        "drugbank-id": "DB00857",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Terbinafine"
                    },
                    {
                        "drugbank-id": "DB00859",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Penicillamine"
                    },
                    {
                        "drugbank-id": "DB00863",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ranitidine"
                    },
                    {
                        "drugbank-id": "DB00876",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Eprosartan"
                    },
                    {
                        "drugbank-id": "DB00884",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Risedronic acid"
                    },
                    {
                        "drugbank-id": "DB00897",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Triazolam"
                    },
                    {
                        "drugbank-id": "DB00898",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ethanol"
                    },
                    {
                        "drugbank-id": "DB00938",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Salmeterol"
                    },
                    {
                        "drugbank-id": "DB00951",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Isoniazid"
                    },
                    {
                        "drugbank-id": "DB00968",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Methyldopa"
                    },
                    {
                        "drugbank-id": "DB00982",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Isotretinoin"
                    },
                    {
                        "drugbank-id": "DB00987",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine"
                    },
                    {
                        "drugbank-id": "DB01004",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ganciclovir"
                    },
                    {
                        "drugbank-id": "DB01006",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Letrozole"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Sulfamethoxazole"
                    },
                    {
                        "drugbank-id": "DB01017",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Minocycline"
                    },
                    {
                        "drugbank-id": "DB01035",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Procainamide"
                    },
                    {
                        "drugbank-id": "DB01039",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Fenofibrate"
                    },
                    {
                        "drugbank-id": "DB01059",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Norfloxacin"
                    },
                    {
                        "drugbank-id": "DB01076",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Atorvastatin"
                    },
                    {
                        "drugbank-id": "DB01088",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Iloprost"
                    },
                    {
                        "drugbank-id": "DB01095",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Fluvastatin"
                    },
                    {
                        "drugbank-id": "DB01097",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Leflunomide"
                    },
                    {
                        "drugbank-id": "DB01098",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Rosuvastatin"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Amiodarone"
                    },
                    {
                        "drugbank-id": "DB01165",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ofloxacin"
                    },
                    {
                        "drugbank-id": "DB01168",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Procarbazine"
                    },
                    {
                        "drugbank-id": "DB01197",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Captopril"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Paclitaxel"
                    },
                    {
                        "drugbank-id": "DB01232",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Saquinavir"
                    },
                    {
                        "drugbank-id": "DB01233",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Metoclopramide"
                    },
                    {
                        "drugbank-id": "DB01234",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Dexamethasone"
                    },
                    {
                        "drugbank-id": "DB01241",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Gemfibrozil"
                    },
                    {
                        "drugbank-id": "DB01248",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Docetaxel"
                    },
                    {
                        "drugbank-id": "DB01393",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Bezafibrate"
                    },
                    {
                        "drugbank-id": "DB01394",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Colchicine"
                    },
                    {
                        "drugbank-id": "DB02703",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Fusidic acid"
                    },
                    {
                        "drugbank-id": "DB05109",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Trabectedin"
                    },
                    {
                        "drugbank-id": "DB06693",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Mevastatin"
                    },
                    {
                        "drugbank-id": "DB06817",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Raltegravir"
                    },
                    {
                        "drugbank-id": "DB08860",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Pitavastatin"
                    },
                    {
                        "drugbank-id": "DB08983",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Etofibrate"
                    },
                    {
                        "drugbank-id": "DB09055",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Acipimox"
                    },
                    {
                        "drugbank-id": "DB09064",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ciprofibrate"
                    },
                    {
                        "drugbank-id": "DB09270",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ubidecarenone"
                    },
                    {
                        "drugbank-id": "DB09289",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Tianeptine"
                    },
                    {
                        "drugbank-id": "DB12554",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine"
                    },
                    {
                        "drugbank-id": "DB13293",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ipecac"
                    },
                    {
                        "drugbank-id": "DB13393",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Emetine"
                    },
                    {
                        "drugbank-id": "DB13433",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Simfibrate"
                    },
                    {
                        "drugbank-id": "DB13460",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ronifibrate"
                    },
                    {
                        "drugbank-id": "DB13780",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Aluminium clofibrate"
                    },
                    {
                        "drugbank-id": "DB13849",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Clofibride"
                    },
                    {
                        "drugbank-id": "DB13873",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Fenofibric acid"
                    },
                    {
                        "drugbank-id": "DB05829",
                        "description": "The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB14513",
                        "description": "Magnesium can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}